Fig. 4From: Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutationSurvival analysis of BM. a The patients repeatedly developed BM after acquiring osimertinib resistance had shorter PFS and OS than patients without BM development after acquiring osimertinib resistance; b The patients that repeatedly developed BM after acquiring osimertinib resistance had shorter PFS and OS than patients without BM development after acquiring osimertinib resistance; c In patients without BM development after obtaining first-generation EGFR-TKI resistance and initial BM developed after acquiring osimertinib resistance, the PFS of the patients with BM developed after acquiring osimertinib resistance was shorter than that without BM development; d The patients with initial BM developed after acquiring osimertinib resistance did not show significant OS advantage over the patients without BM development. e Of the patients that developed BM after osimertinib group, patients with initial BM developed after obtaining first-generation EGFR-TKI resistance had shorter PFS than those without BM development; f In the patients without BM development after osimertinib group, the patients without BM development after obtaining first-generation EGFR-TKI resistance failed to show superior PFS than those with BM developedBack to article page